FOLD
Featured PickAmicus Therapeutics, Inc.
Real picks. Real tracking. We bet on one stock daily and show you exactly how it plays out.
AI Confidence Score
82
Entry Price
$14.33
Current Price
$39.18
Total Return
+0.00%
vs SPY
+0.00%
As of Close 2026-03-05
Executive Summary
Amicus Therapeutics (FOLD) confirms its status as the ultimate 'Risk-Off' sanctuary following the **March 3rd stockholder approval** of the $4.8B BioMarin acquisition. While the broader SPY fractures under geopolitical strain, FOLD offers a decoupled arbitrage opportunity, effectively locked into the $14.50 deal price. This 'Quiet Storm' setup acts as a defensive vault, allowing capital to capture the remaining merger spread while insulating against the volatility crushing high-beta tech names.
Technical Context
Setup
Price action is tightly pinned at 52-week highs (-0.3%) with volume contracting to 0.9x average, confirming institutional holding patterns ahead of the Q2 deal close.
Invalidation (Stop)
A close below $14.15 would signal unexpected deal turbulence or spread widening beyond the typical arbitrage band.
Runner-ups
Recent Performance History
22 Total Picks • 57% Win Rate (7d)
| Date | Ticker | Entry | Last | Gain/Loss | 7d | 30d | 60d |
|---|---|---|---|---|---|---|---|
| 2026-02-24 | AES | $16.27 | $14.22 | -12.60% | -12.60% | N/A | N/A |
| 2026-02-23 | PRA | $24.40 | $24.64 | +0.98% | +0.98% | N/A | N/A |
| 2026-02-20 | ST | $38.35 | $34.24 | -10.72% | -10.72% | N/A | N/A |
| 2026-02-19 | FTI | $61.76 | $64.44 | +4.34% | +4.34% | N/A | N/A |
| 2026-02-18 | FOLD | $14.34 | $14.33 | -0.07% | -0.07% | N/A | N/A |
| 2026-02-17 | ROL | $60.08 | $58.17 | -3.18% | +0.72% | N/A | N/A |
| 2026-02-13 | AES | $16.28 | $14.22 | -12.65% | +1.41% | N/A | N/A |
| 2026-02-12 | PRA | $24.53 | $24.64 | +0.45% | -0.61% | N/A | N/A |
| 2026-02-11 | AES | $16.44 | $14.22 | -13.50% | -0.91% | N/A | N/A |
| 2026-02-10 | RRX | $222.74 | $198.94 | -10.69% | -1.66% | N/A | N/A |
Schema v1.0 | Pipeline v1.2.0